Monte Rosa Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
GLUE$10.50-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (Unaudited)
| September 30, | December 31, | |
|---|---|---|
| (in thousands, except share and per share amounts) | 2026 | 2025 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $45,180 | $129,883 |
| Marketable securities | 532,546 | 247,221 |
| Collaboration receivable | 50,000 | 7,000 |
| Other receivables | 7,624 | 4,600 |
| Prepaid expenses and other current assets | 4,715 | 4,481 |
| Total current assets | 640,065 | 393,185 |
| Property and equipment, net | 28,632 | 25,986 |
| Operating lease right-of-use assets | 23,343 | 24,386 |
| Restricted cash | 4,918 | 4,954 |
| Other long-term assets | 767 | 148 |
| Total assets | $697,725 | $448,659 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $3,347 | $3,550 |
| Accrued expenses and other current liabilities | 33,414 | 26,694 |
| Current deferred revenue | 21,098 | 29,571 |
| Current portion of operating lease liability | 4,187 | 4,397 |
| Total current liabilities | 62,046 | 64,212 |
| Deferred revenue, net of current | 102,261 | 111,332 |
| Defined benefit plan liability | 5,131 | 5,265 |
| Operating lease liability, net of current | 32,079 | 34,794 |
| Total liabilities | 201,517 | 215,603 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized | — | — |
| Common stock, $0.0001 par value; 500,000,000 shares authorized, 85,431,211 and 65,543,723 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 9 | 7 |
| Additional paid-in capital | 1,064,442 | 714,090 |
| Accumulated other comprehensive loss | (6,192) | (3,827) |
| Accumulated deficit | (562,051) | (477,214) |
| Total stockholders’ equity | 496,208 | 233,056 |
| Total liabilities and stockholders’ equity | $697,725 | $448,659 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.